PET Imaging

PET (Positron Emission Tomography) is a nuclear medicine imaging modality used to visualize the structures within the human body. In most cases, a PET scan is performed in conjunction with a computed tomography (CT) scan, a process known as hybrid imaging.

Consequently, these noninvasive imaging procedures are rapid and sensitive to anatomical and biological changes in the body and provide essential information about how a particular disease behaves in patients, for example, in staging, restaging, and assessing cancer treatment response.

During the PET imaging procedure, the patient is injected with a low radiopharmaceutical (radiotracer) dose such as 18FDG, Na18F, 68Ga-PSMA and 68Ga-DOTATATE. However, conventional CT and MRI (magnetic resonance imaging) use X-rays to obtain 3D anatomical images. An injected radiation dose into the human body distributes to specific areas distributed close metabolism when using 18FDG to identify absorptivity used in the body.

PET imaging also enables the determination of a tumour’s metabolism rate to see if it is still active. A further hybrid uses PET and MRI to facilitate improvement in the visualisation of specific structures, for example, in the brain and pelvic organs.

In another situation regarding lung cancer diagnosis, it is paramount for the oncologist to determine if the patient requires curative surgery and chemotherapy or only palliative chemotherapy. Therefore, to enable this decision, using 18FDG radiotracer in a PET-CT scan will allow the oncologist to verify if the lung cancer has spread to a particular lymph node.

The essence of PET imaging is to evaluate metabolic changes that precede anatomical changes, which MRI observes. Consequently, positron emission tomography imaging detects tumours early and assesses dementia and seizures. It also observes the functions of the heart and evaluates inflammatory diseases.

You are here:
home » PET imaging

brain scan using Pittsburgh Compound-B (PIB) PET imaging, highlighting amyloid plaques as bright spots within the brain
Nuclear Medicine Imaging

The Discovery and Development of Pittsburgh Compound-B (PIB): A Breakthrough in Alzheimer’s Disease Research

Pittsburgh Compound-B allows researchers to visualise amyloid plaques in the brain, aiding in Alzheimer’s disease diagnosis and study.

The Discovery and Development of Pittsburgh Compound-B (PIB): A Breakthrough in Alzheimer’s Disease Research Read Post »

, , ,
Medical technologies revolutionise diagnostics, treatments, patient monitoring, enhancing healthcare, and improving overall quality of life globally.
Medical Technologies

Harnessing the Power of Deep Learning Reconstruction for Enhanced Medical Imaging and Diagnosis

Medical imaging advancements, aided by deep learning reconstruction, enhance diagnosis accuracy and efficiency, overcoming traditional limitations.

Harnessing the Power of Deep Learning Reconstruction for Enhanced Medical Imaging and Diagnosis Read Post »

, , ,
FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Copper-64 DOTATE: A Promising Radiopharmaceutical in Diagnostic Imaging and Targeted Therapy

Copper-64 DOTATE, a diagnostic radiopharmaceutical, effectively targets neuroendocrine tumours, enabling precise imaging and personalised treatment plans for cancer patients.

Copper-64 DOTATE: A Promising Radiopharmaceutical in Diagnostic Imaging and Targeted Therapy Read Post »

, , ,
Inaugural Editorial Review of Diagnostic Imaging
Journal of Diagnostic Imaging in Therapy

Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy

Topics on PET imaging, automated radiosynthesis, breast cancer, prostate cancer therapy and ultrasound.

Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy Read Post »

, , , , , ,
Scroll to Top